Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2022

Transgene Announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings

Published 15 December 2022
Categorized as 2022, Press release

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Published 14 November 2022
Categorized as 2022, BT-001, dates, Press release

Transgene reports business update and Q3 2022 financial position

TRANSGENE reports business update and Q3 2022 financial position

Published 7 November 2022
Categorized as 2022, 2022, Press release, dates, dates, Invir.IO, Press release

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001

Published 2 November 2022
Categorized as 2022, 2022, Press release, dates, Invir.IO, Press release, TG4001, TG4001

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Published 27 September 2022
Categorized as 2022, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Published 12 September 2022
Categorized as 2022, Invir.IO, Press release, TG6002

Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022

2022 Half-year results and business update

Published 7 September 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings

Published 31 August 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Transgene and bioinvent announce clinical collaboration

Published 28 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene and BioInvent announce positive progress for BT-001

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 27 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu